Literature DB >> 12488707

Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients.

Arnoldo J Riquelme1, Mario A Calvo, Ana M Guzmán, María S Depix, Patricia García, Carlos Pérez, Marco Arrese, Jaime A Labarca.   

Abstract

Saccharomyces cerevisiae is widely used as a probiotic compound. Clinical data suggest that this agent is safe and effective. We report two cases of fungemia caused by S. cerevisiae occurring in immunosuppressed patients treated orally with S. boulardii Molecular typing confirmed clonality in isolate strains from patients and the capsule. Physicians caring for immunosuppressed patients must be aware of this potential serious complication of probiotic use.

Entities:  

Mesh:

Year:  2003        PMID: 12488707     DOI: 10.1097/00004836-200301000-00013

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  31 in total

1.  Use of probiotics in gastrointestinal disorders: what to recommend?

Authors:  Elizabeth C Verna; Susan Lucak
Journal:  Therap Adv Gastroenterol       Date:  2010-09       Impact factor: 4.409

2.  Probiotics for Crohn's disease: what have we learned?

Authors:  C Prantera
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

3.  Lactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury.

Authors:  Yuhua Wang; Yanlong Liu; Anju Sidhu; Zhenhua Ma; Craig McClain; Wenke Feng
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-04-26       Impact factor: 4.052

Review 4.  Risk and safety of probiotics.

Authors:  Shira Doron; David R Snydman
Journal:  Clin Infect Dis       Date:  2015-05-15       Impact factor: 9.079

Review 5.  Probiotics for antibiotic-associated diarrhea: do we have a verdict?

Authors:  Iyad Issa; Rami Moucari
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

6.  Probiotics as therapy in gastroenterology: a study of physician opinions and recommendations.

Authors:  Michael D Williams; Christina Y Ha; Matthew A Ciorba
Journal:  J Clin Gastroenterol       Date:  2010-10       Impact factor: 3.062

Review 7.  Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.

Authors:  Lauren E Hudson; Sarah E Anderson; Anita H Corbett; Tracey J Lamb
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

8.  Typing of Saccharomyces cerevisiae clinical strains by using microsatellite sequence polymorphism.

Authors:  J Y Malgoire; S Bertout; F Renaud; J M Bastide; M Mallié
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

9.  Clostridium difficile infection: emerging concepts and treatments.

Authors:  Thomas Mathew; Philip A Higginbottom
Journal:  Curr Gastroenterol Rep       Date:  2008-08

10.  Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells.

Authors:  Satya Prakash; Aleksandra Malgorzata Urbanska
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.